Research graph
References from Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials. Local targets link to admitted publications; unresolved targets remain external evidence.
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
10.1097/hep.0000000000000647 · 2024 · External reference
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
10.1016/s2468-1253(23)00068-7 · 2023 · External reference
Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis
10.2337/dc17-1902 · 2018 · External reference
The obesity epidemic and bariatric trends
10.1016/j.cps.2018.08.001 · 2019 · External reference
Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a deadly synergy
10.17925/ee.2024.20.2.2 · 2024 · External reference
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
10.1097/hep.0000000000000004 · 2023 · External reference
Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk
10.2174/1570161115666170621082910 · 2018 · External reference
Nonalcoholic steatohepatitis: a review
10.1001/jama.2020.2298 · 2020 · External reference
Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
10.1016/j.cld.2017.08.007 · 2018 · External reference
Pathogenesis of NASH: the impact of multiple pathways
10.1007/s11901-018-0425-7 · 2018 · External reference
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
10.1056/nejmoa2413258 · 2025 · External reference
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
10.1097/hep.0000000000000323 · 2023 · External reference
Glucagon-like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials
10.3390/metabo11020073 · 2021 · External reference
GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease
10.1001/jamainternmed.2024.4661 · 2024 · External reference
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
10.1016/s2213-8587(22)00070-5 · 2022 · External reference
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
10.1056/nejmoa2401943 · 2024 · External reference
Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes
10.2337/dc19-1892 · 2020 · External reference
RoB 2: A revised tool for assessing risk of bias in randomised trials
2019 · External reference
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
10.1016/j.jhep.2023.05.013 · 2023 · External reference
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
10.1016/j.jhep.2024.07.006 · 2025 · External reference
A Phase 2 randomized trial of survodutide in MASH and fibrosis
10.1056/nejmoa2401755 · 2024 · External reference
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
10.1007/s00125-023-06053-9 · 2024 · External reference
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
10.1016/j.jhep.2024.06.003 · 2024 · External reference
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study
10.1016/j.cct.2023.107176 · 2023 · External reference
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
10.1038/s41591-024-03018-2 · 2024 · External reference
Tirzepatide as compared with semaglutide for the treatment of obesity
10.1056/nejmoa2416394 · 2025 · External reference
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
10.1016/s0140-6736(18)32260-8 · 2018 · External reference
